Bronchoalveolar lavage as a tool to predict, diagnose and understand bronchiolitis obliterans syndrome

American Journal of Transplantation

Volumn 13, Issue 3, 2013, Pages 552-561

  Kennedy, V E ^a   Todd, J L ^a,b   Palmer, S M ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

bronchiolitis obliterans syndrome; Bronchoalveolar lavage; lung transplantation

Indexed keywords

ALPHA DEFENSIN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CYTOKINE; GELATINASE B; GROWTH FACTOR; INTERLEUKIN 8; MATRIX METALLOPROTEINASE;

BRONCHIOLITIS OBLITERANS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; INNATE IMMUNITY; LUNG LAVAGE; LUNG TRANSPLANTATION; NEUTROPHIL COUNT; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SAMPLE SIZE;

BIOLOGICAL MARKERS; BRONCHIOLITIS OBLITERANS; BRONCHOALVEOLAR LAVAGE FLUID; HUMANS; SYNDROME;

EID: 84874402517     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12091     Document Type: Review

References (112)

1. Christie JD, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fifth official adult lung and heart/lung transplantation report-2008. J Heart Lung Transplant 2008; 27: 957-969.
2. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.
3. Todd JL, Palmer SM,. Bronchiolitis obliterans syndrome: The final frontier for lung transplantation. Chest 2011; 140: 502-508.
4. Davis CS, Gagermeier J, Dilling D, et al. A review of the potential applications and controversies of non-invasive testing for biomarkers of aspiration in the lung transplant population. Clin Transplant 2010; 24: E54-E61.
5. Anderson RL, Hiemstra PS, Ward C, et al. Antimicrobial peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Eur Respir J 2008; 32: 670-677.
6. Banerjee B, Ling KM, Sutanto EN, et al. The airway epithelium is a direct source of matrix degrading enzymes in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2011; 30: 1175-1185.
7. Behr J, Maier K, Braun B, Schwaiblmair M, Vogelmeier C,. Evidence for oxidative stress in bronchiolitis obliterans syndrome after lung and heart-lung transplantation. Transplantation 2000; 69: 1856-1860.
8. Belperio JA, DiGiovine B, Keane MP, et al. Interleukin-1 receptor antagonist as a biomarker for bronchiolitis obliterans syndrome in lung transplant recipients. Transplantation 2002; 73: 591-599.
9. Devouassoux G, Drouet C, Pin I, et al. Alveolar neutrophilia is a predictor for the bronchiolitis obliterans syndrome, and increases with degree of severity. Transpl Immunol 2002; 10: 303-310.
10. DiGiovine B, Lynch JP, 3rd, Martinez FJ, et al. Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: Role of IL-8. J Immunol 1996; 157: 4194-4202.
11. D'Ovidio F, Mura M, Tsang M, et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg 2005; 129: 1144-1152.
12. Elssner A, Jaumann F, Dobmann S, et al. Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: Proinflammatory role of bronchial epithelial cells. Transplantation 2000; 70: 362-367.
13. Hertz MI, Henke CA, Nakhleh RE, et al. Obliterative bronchiolitis after lung transplantation: A fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad Sci USA 1992; 89: 10385-10389.
14. Hirsch J, Elssner A, Mazur G, et al. Bronchiolitis obliterans syndrome after (heart-)lung transplantation. Impaired antiprotease defense and increased oxidant activity. Am J Respir Crit Care Med 1999; 160: 1640-1646.
15. Hubner RH, Meffert S, Mundt U, et al. Matrix metalloproteinase-9 in bronchiolitis obliterans syndrome after lung transplantation. Eur Respir J 2005; 25: 494-501.
16. Laan M, Linden A, Riise GC,. IL-16 in the airways of lung allograft recipients with acute rejection or obliterative bronchiolitis. Clin Exp Immunol 2003; 133: 290-296.
17. Magnan A, Mege JL, Escallier JC, et al. Balance between alveolar macrophage IL-6 and TGF-beta in lung-transplant recipients. Marseille and Montreal Lung Transplantation Group. Am J Respir Crit Care Med 1996; 153: 1431-1436.
18. Mamessier E, Milhe F, Badier M, Thomas P, Magnan A, Reynaud-Gaubert M,. Comparison of induced sputum and bronchoalveolar lavage in lung transplant recipients. J Heart Lung Transplant 2006; 25: 523-532.
19. Neurohr C, Huppmann P, Samweber B, et al. Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recipients. J Heart Lung Transplant 2009; 28: 468-474.
20. Nord M, Schubert K, Cassel TN, Andersson O, Riise GC,. Decreased serum and bronchoalveolar lavage levels of Clara cell secretory protein (CC16) is associated with bronchiolitis obliterans syndrome and airway neutrophilia in lung transplant recipients. Transplantation 2002; 73: 1264-1269.
21. Nunley D, Dauber J, Iacono A, et al. Unopposed neutrophil elastase in bronchoalveolar lavage from transplant recipients with cystic fibrosis. Am J Respir Crit Care Med 1999; 159: 258-261.
22. Reid D, Snell G, Ward C, et al. Iron overload and nitric oxide-derived oxidative stress following lung transplantation. J Heart Lung Transplant 2001; 20: 840-849.
23. Reynaud-Gaubert M, Marin V, Thirion X, et al. Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of post-transplant airway obliteration. J Heart Lung Transplant 2002; 21: 721-730.
24. Reynaud-Gaubert M, Thomas P, Badier M, Cau P, Giudicelli R, Fuentes P,. Early detection of airway involvement in obliterative bronchiolitis after lung transplantation. Functional and bronchoalveolar lavage cell findings. Am J Respir Crit Care Med 2000; 161: 1924-1929.
25. Riise GC, Andersson BA, Kjellstrom C, et al. Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant. Eur Respir J 1999; 14: 1123-1130.
26. Riise GC, Williams A, Kjellstrom C, Schersten H, Andersson BA, Kelly FJ,. Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung. Eur Respir J 1998; 12: 82-88.
27. Scholma J, Slebos DJ, Boezen HM, et al. Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med. 2000; 162: 2221-2225.
28. Slebos DJ, Postma DS, Koeter GH, Van Der Bij W, Boezen M, Kauffman HF,. Bronchoalveolar lavage fluid characteristics in acute and chronic lung transplant rejection. J Heart Lung Transplant 2004; 23: 532-540.
29. Vanaudenaerde BM, De Vleeschauwer SI, Vos R, et al. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2008; 8: 1911-1920.
30. Vanaudenaerde BM, Wuyts WA, Geudens N, et al. Broncho-alveolar lavage fluid recovery correlates with airway neutrophilia in lung transplant patients. Respir Med 2008; 102: 339-347.
31. Vos R, Vanaudenaerde BM, De Vleeschauwer SI, et al. Circulating and intrapulmonary C-reactive protein: A predictor of bronchiolitis obliterans syndrome and pulmonary allograft outcome. J Heart Lung Transplant 2009; 28: 799-807.
32. Ward C, Snell GI, Zheng L, et al. Endobronchial biopsy and bronchoalveolar lavage in stable lung transplant recipients and chronic rejection. Am J Respir Crit Care Med 1998; 158: 84-91.
33. Ward C, Whitford H, Snell G, et al. Bronchoalveolar lavage macrophage and lymphocyte phenotypes in lung transplant recipients. J Heart Lung Transplant 2001; 20: 1064-1074.
34. Whitford HM, Orsida B, Pais M, et al. Features of bronchoalveolar lavage (BAL) in lung transplant recipients (LTR) who later develop bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant 2001; 20: 176.
35. Zheng L, Walters EH, Ward C, et al. Airway neutrophilia in stable and bronchiolitis obliterans syndrome patients following lung transplantation. Thorax 2000; 55: 53-59.
36. Zheng L, Whitford HM, Orsida B, et al. The dynamics and associations of airway neutrophilia post lung transplantation. Am J Transplant 2006; 6: 599-608.
37. Reynaud-Gaubert M, Thomas P, Gregoire R, et al. Clinical utility of bronchoalveolar lavage cell phenotype analyses in the postoperative monitoring of lung transplant recipients. Eur J Cardiothorac Surg 2002; 21: 60-66.
38. Elssner A, Vogelmeier C,. The role of neutrophils in the pathogenesis of obliterative bronchiolitis after lung transplantation. Transpl Infect Dis 2001; 3: 168-176.
39. Mertens V, Blondeau K, Van Oudenhove L, et al. Bile acids aspiration reduces survival in lung transplant recipients with BOS despite azithromycin. Am J Transplant 2011; 11: 329-335.
40. Ohshimo S, Bonella F, Sommerwerck U, et al. Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation. J Heart Lung Transplant 2011; 30: 1374-1380.
41. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T,. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008; 85: 36-41.
42. Stovold R, Forrest IA, Corris PA, et al. Pepsin, a biomarker of gastric aspiration in lung allografts: A putative association with rejection. Am J Respir Crit Care Med 2007; 175: 1298-1303.
43. Vanaudenaerde BM, Meyts I, Vos R, et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008; 32: 832-843.
44. Agostini C, Calabrese F, Rea F, et al. Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 2001; 158: 1703-1711.
45. Bhorade SM, Chen H, Molinero L, et al. Decreased percentage of CD4+FoxP3+ cells in bronchoalveolar lavage from lung transplant recipients correlates with development of bronchiolitis obliterans syndrome. Transplantation 2010; 90: 540-546.
46. Gregson AL, Hoji A, Palchevskiy V, et al. Protection against bronchiolitis obliterans syndrome is associated with allograft CCR7+ CD45RA- T regulatory cells. PLoS One 2010; 5: e11354.
47. Hodge G, Hodge S, Chambers D, Reynolds PN, Holmes M,. Bronchiolitis obliterans syndrome is associated with absence of suppression of peripheral blood Th1 proinflammatory cytokines. Transplantation 2009; 88: 211-218.
48. Whitehead BF, Stoehr C, Finkle C, et al. Analysis of bronchoalveolar lavage from human lung transplant recipients by flow cytometry. Respir Med 1995; 89: 27-34.
49. Whitford H, Walters EH, Levvey B, et al. Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: A double-blind, placebo-controlled trial. Transplantation 2002; 73: 1793-1799.
50. Zheng L, Orsida B, Whitford H, et al. Longitudinal comparisons of lymphocytes and subtypes between airway wall and bronchoalveolar lavage after human lung transplantation. Transplantation 2005; 80: 185-192.
51. Badri L, Murray S, Liu LX, et al. Mesenchymal stromal cells in bronchoalveolar lavage as predictors of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2011; 183: 1062-1070.
52. Salama M, Andrukhova O, Jaksch P, et al. Endothelin-1 governs proliferation and migration of bronchoalveolar lavage-derived lung mesenchymal stem cells in bronchiolitis obliterans syndrome. Transplantation 2011; 92: 155-162.
53. Walker N, Badri L, Wettlaufer S, et al. Resident tissue-specific mesenchymal progenitor cells contribute to fibrogenesis in human lung allografts. Am J Pathol 2011; 178: 2461-2469.
54. Walker NM, Badri LN, Wadhwa A, Wettlaufer S, Peters-Golden M, Lama VN,. Prostaglandin E2 as an inhibitory modulator of fibrogenesis in human lung allografts. Am J Respir Crit Care Med 2012; 185: 77-84.
55. Hardison MT, Galin FS, Calderon CE, et al. The presence of a matrix-derived neutrophil chemoattractant in bronchiolitis obliterans syndrome after lung transplantation. J Immunol 2009; 182: 4423-4431.
56. Meloni F, Vitulo P, Cascina A, et al. Bronchoalveolar lavage cytokine profile in a cohort of lung transplant recipients: A predictive role of interleukin-12 with respect to onset of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2004; 23: 1053-1060.
57. Ramirez AM, Nunley DR, Rojas M, Roman J,. Activation of tissue remodeling precedes obliterative bronchiolitis in lung transplant recipients. Biomark Insights. 2008; 3: 351-359.
58. Verleden SE, Vandooren J, Vos R, et al. Azithromycin decreases MMP-9 expression in the airways of lung transplant recipients. Transpl Immunol 2011; 25: 159-162.
59. Verleden SE, Vos R, Mertens V, et al. Heterogeneity of chronic lung allograft dysfunction: Insights from protein expression in broncho alveolar lavage. J Heart Lung Transplant 2011; 30: 667-673.
60. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA,. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994; 91: 3652-3656.
61. Taub DD, Proost P, Murphy WJ, et al. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest 1995; 95: 1370-1376.
62. Belperio JA, Keane MP, Burdick MD, et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest 2001; 108: 547-556.
63. Neujahr DC, Perez SD, Mohammed A, et al. Cumulative exposure to gamma interferon-dependent chemokines CXCL9 and CXCL10 correlates with worse outcome after lung transplant. Am J Transplant 2012; 12: 438-446.
64. Salama M, Jaksch P, Andrukhova O, Taghavi S, Klepetko W, Aharinejad S,. Endothelin-1 is a useful biomarker for early detection of bronchiolitis obliterans in lung transplant recipients. J Thorac Cardiovasc Surg 2010; 140: 1422-1427.
65. Belperio JA, Keane MP, Burdick MD, et al. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 2002; 169: 1037-1049.
66. Nelsestuen GL, Martinez MB, Hertz MI, Savik K, Wendt CH,. Proteomic identification of human neutrophil alpha-defensins in chronic lung allograft rejection. Proteomics 2005 5: 1705-1713.
67. Saini D, Angaswamy N, Tiriveedhi V, et al. Synergistic effect of antibodies to human leukocyte antigens and defensins in pathogenesis of bronchiolitis obliterans syndrome after human lung transplantation. J Heart Lung Transplant 2010; 29: 1330-1336.
68. Wolf T, Oumeraci T, Gottlieb J, et al. Proteomic bronchiolitis obliterans syndrome risk monitoring in lung transplant recipients. Transplantation 2011; 92: 477-485.
69. Zhang Y, Wroblewski M, Hertz MI, Wendt CH, Cervenka TM, Nelsestuen GL,. Analysis of chronic lung transplant rejection by MALDI-TOF profiles of bronchoalveolar lavage fluid. Proteomics 2006; 6: 1001-1010.
70. Murphy CJ, Foster BA, Mannis MJ, Selsted ME, Reid TW,. Defensins are mitogenic for epithelial cells and fibroblasts. J Cell Physiol 1993; 155: 408-413.
71. Li J, Raghunath M, Tan D, Lareu RR, Chen Z, Beuerman RW,. Defensins HNP1 and HBD2 stimulation of wound-associated responses in human conjunctival fibroblasts. Invest Ophthalmol Vis Sci 2006; 47: 3811-3819.
72. Oono T, Shirafuji Y, Huh WK, Akiyama H, Iwatsuki K,. Effects of human neutrophil peptide-1 on the expression of interstitial collagenase and type I collagen in human dermal fibroblasts. Arch Dermatol Res 2002; 294: 185-189.
73. Riise GC, Ericson P, Bozinovski S, Yoshihara S, Anderson GP, Linden A,. Increased net gelatinase but not serine protease activity in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2010; 29: 800-807.
74. D'Ovidio F, Mura M, Ridsdale R, et al. The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. Am J Transplant 2006; 6: 1930-1938.
75. Meloni F, Salvini R, Bardoni AM, et al. Bronchoalveolar lavage fluid proteome in bronchiolitis obliterans syndrome: Possible role for surfactant protein A in disease onset. J Heart Lung Transplant 2007; 26: 1135-1143.
76. Kosanam H, Sato M, Batruch I, et al. Differential proteomic analysis of bronchoalveolar lavage fluid from lung transplant patients with and without chronic graft dysfunction. Clin Biochem 2012; 45: 223-230.
77. Scott JP, Holt DW, Wallwork J,. Neutrophil elastase and obliterative bronchiolitis. Transpl Int 1994; 7: S402-S403.
78. Nagase H, Woessner JF, Jr., Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494.
79. Parks WC, Shapiro SD,. Matrix metalloproteinases in lung biology. Respir Res 2001; 2: 10-19.
80. Atkinson JJ, Senior RM,. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003; 28: 12-24.
81. Parks WC,. Matrix metalloproteinases in lung repair. Eur Respir J 2003; 44: 36s-38s.
82. Taghavi S, Krenn K, Jaksch P, Klepetko W, Aharinejad S,. Broncho-alveolar lavage matrix metalloproteases as a sensitive measure of bronchiolitis obliterans. Am J Transplant 2005; 5: 1548-1552.
83. Madill J, Aghdassi E, Arendt B, et al. Lung transplantation: Does oxidative stress contribute to the development of bronchiolitis obliterans syndrome ? Transplant Rev 2009; 23: 103-110.
84. Madill J, Aghdassi E, Arendt BM, et al. Oxidative stress and nutritional intakes in lung patients with bronchiolitis obliterans syndrome. Transplant Proc 2009; 41: 3838-3844.
85. Sato M, Waddell TK, Wagnetz U, et al. Restrictive allograft syndrome (RAS): A novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 2011; 30: 735-742.
86. Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012; 185: 1004-1014.
87. Belperio JA, Keane MP, Burdick MD, et al. Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 2005; 115: 1150-1162.
88. Magnan A, Mege JL, Reynaud M, et al. Monitoring of alveolar macrophage production of tumor necrosis factor-alpha and interleukin-6 in lung transplant recipients. Marseille and Montreal Lung Transplantation Group. Am J Respir Crit Care Med 1994; 150: 684-689.
89. Meyer KC, Nunley DR, Dauber JH, et al. Neutrophils, unopposed neutrophil elastase, and alpha1-antiprotease defenses following human lung transplantation. Am J Respir Crit Care Med 2001; 164: 97-102.
90. Langenbach SY, Zheng L, McWilliams T, et al. Airway vascular changes after lung transplant: Potential contribution to the pathophysiology of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2005; 24: 1550-1556.
91. Ross DJ, Cole AM, Yoshioka D, et al. Increased bronchoalveolar lavage human beta-defensin type 2 in bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004; 78: 1222-1224.
92. Reinsmoen NL, Bolman RM, Savik K, Butters K, Hertz MI,. Are multiple immunopathogenetic events occurring during the development of obliterative bronchiolitis and acute rejection? Transplantation 1993; 55: 1040-1044.
93. Bargagli E, Madioni C, Prasse A, et al. Eosinophilic cationic protein in bronchoalveolar lavage fluid of lung transplant patients. Clin Chem Lab Med 2008; 46: 563-564.
94. O'Connell PJ, Mba-Jonas A, Leverson GE, et al. Stable lung allograft outcome correlates with the presence of intragraft donor-derived leukocytes. Transplantation 1998; 66: 1167-1174.
95. Reinsmoen NL, Bolman RM, Savik K, Butters K, Hertz M,. Differentiation of class I- and class II-directed donor-specific alloreactivity in bronchoalveolar lavage lymphocytes from lung transplant recipients. Transplantation 1992; 53: 181-189.
96. Carroll KE, Dean MM, Heatley SL, et al. High levels of mannose-binding lectin are associated with poor outcomes after lung transplantation. Transplantation 2011; 91: 1044-1049.
97. Hodge S, Dean M, Hodge G, Holmes M, Reynolds PN,. Decreased efferocytosis and mannose binding lectin in the airway in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2011; 30: 589-595.
98. Vos R, Vanaudenaerde BM, De Vleeschauwer SI, et al. C-reactive protein in bronchoalveolar lavage fluid is associated with markers of airway inflammation after lung transplantation. Transplant Proc 2009; 41: 3409-3413.
99. Sundaresan S, Alevy YG, Steward N, et al. Cytokine gene transcripts for tumor necrosis factor-alpha, interleukin-2, and interferon-gamma in human pulmonary allografts. J Heart Lung Transplant 1995; 14: 512-518.
100. Keane MP, Gomperts BN, Weigt S, et al. IL-13 is pivotal in the fibro-obliterative process of bronchiolitis obliterans syndrome. J Immunol 2007; 178: 511-519.
101. Sandmeier P, Speich R, Grebski E, et al. Iron accumulation in lung allografts is associated with acute rejection but not with adverse outcome. Chest 2005; 128: 1379-1384.
102. Charpin JM, Valcke J, Kettaneh L, Epardeau B, Stern M, Israel-Biet D,. Peaks of transforming growth factor-beta mRNA in alveolar cells of lung transplant recipients as an early marker of chronic rejection. Transplantation 1998; 65: 752-755.
103. Bergmann M, Tiroke A, Schafer H, Barth J, Haverich A,. Gene expression of profibrotic mediators in bronchiolitis obliterans syndrome after lung transplantation. Scand Cardiovasc J 1998; 32: 97-103.
104. Hodge S, Holmes M, Banerjee B, et al. Posttransplant bronchiolitis obliterans syndrome is associated with bronchial epithelial to mesenchymal transition. Am J Transplant 2009; 9: 727-733.
105. Jonosono M, Fang KC, Keith FM, et al. Measurement of fibroblast proliferative activity in bronchoalveolar lavage fluid in the analysis of obliterative bronchiolitis among lung transplant recipients. J Heart Lung Transplant 1999; 18: 972-985.
106. Meyer KC, Cardoni AL, Xiang Z, Cornwell RD, Love RB,. Vascular endothelial growth factor in human lung transplantation. Chest 2001; 119: 137-143.
107. Meloni F, Solari N, Miserere S, et al. Chemokine redundancy in BOS pathogenesis. A possible role also for the CC chemokines: MIP3-beta, MIP3-alpha, MDC and their specific receptors. Transpl Immunol 2008; 18: 275-280.
108. Wood KL, Nunley DR, Moffatt-Bruce S, et al. The role of heat shock protein 27 in bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010; 29: 786-791.
109. Charpin JM, Stern M, Grenet D, Israel-Biet D,. Insulinlike growth factor-1 in lung transplants with obliterative bronchiolitis. Am J Respir Crit Care Med 2000; 161: 1991-1998.
110. Hodge S, Hodge G, Ahern J, et al. Increased levels of T cell granzyme b in bronchiolitis obliterans syndrome are not suppressed adequately by current immunosuppressive regimens. Clin Exp Immunol 2009; 158: 230-236.
111. de Andrade JA, Christie JD, Alexander CB, et al. Association of reactive nitrogen species metabolites, myeloperoxidase, and airway inflammation in lung transplants. J Investig Med 2001; 49: 166-172.
112. Courtade M, Carrera G, Paternain JL, et al. Metallothionein expression in human lung and its varying levels after lung transplantation. Toulouse Lung Transplantation Group. Chest 1998; 113: 371-378.